secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2024-07-17T23:59:59+00:00
Accession:  0001104659-24-080571
Event type: other_material
Sentiment:  positive
Materiality: 0.25
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel Therapeutics amends ARx supply agreement to reduce minimum annual payments over next three years
--------------------------------------------------------------------------------

- Amendment reduces specified minimum annual payment due to ARx for next three years starting 2024.
- Thereafter, minimum annual payments only required if FDA approves sNDA or NDA for listed indications.
- No specific financial terms or amounts disclosed in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465924080571/0001104659-24-080571-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465924080571/tm2419377d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-080571

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer